KIM-1 is a good prognostic and predictive biomarker in advanced renal cell carcinoma
KIM-1 is a good prognostic and predictive biomarker in advanced renal cell carcinoma
Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer
UGN-102 shows better results after 12 months of treatment for low-grade intermediate-risk NMIBC
177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in mCRPC
CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC
HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide, abiraterone acetate plus prednisolone
Enfortumab vedotin in combination with pembrolizumab shows improved survival rates in la/mUC
Ageing and cancer: Inflammation promotes ageing-associated oncogenesis in the lung
Low-dose aspirin can reduce recurrence rates in colorectal cancer patients with PI3K pathway alterations
Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal compared to nivolumab monotherapy
Assessment and management of toxic effects of cancer therapy in elderly patients in Tunisia
The use of IORT at Merit Health Surgical Oncology